Cannabinoid-Based Ocular Therapies and Formulations
暂无分享,去创建一个
[1] S. Majumdar,et al. Cannabidiol Loaded Topical Ophthalmic Nanoemulsion Lowers Intraocular Pressure in Normotensive Dutch-Belted Rabbits , 2022, Pharmaceutics.
[2] Huifang Zhou,et al. Immune modulating nanoparticles for the treatment of ocular diseases , 2022, Journal of Nanobiotechnology.
[3] Farhang Modaresi,et al. The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes , 2022, Pharmaceutical Medicine.
[4] L. Phillips,et al. The value of real world evidence: The case of medical cannabis , 2022, Frontiers in Psychiatry.
[5] R. B. Walker,et al. Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery , 2022, International journal of molecular sciences.
[6] M. S. Akhtar,et al. Development of cannabidiol nanoemulsion for direct nose to brain delivery: statistical optimization, in vitro and in vivo evaluation , 2022, Biomedical materials.
[7] C. Brullo,et al. Nanotechnology for Pediatric Retinoblastoma Therapy , 2022, Pharmaceuticals.
[8] A. Hoffman,et al. Strategies for enhancing the oral bioavailability of cannabinoids , 2022, Expert opinion on drug metabolism & toxicology.
[9] P. Couvreur,et al. Micro- and Nanocarriers for pain alleviation. , 2022, Advanced drug delivery reviews.
[10] Bryan M. Williams,et al. Automatic detection of glaucoma via fundus imaging and artificial intelligence: A review , 2022, Survey of ophthalmology.
[11] S. Benita,et al. The dose-dependent effect of a stabilized cannabidiol nanoemulsion on ocular surface inflammation and intraocular pressure. , 2022, International journal of pharmaceutics.
[12] Sumeet Gupta,et al. Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy—An Overview on Recent Advances , 2022, Pharmaceutics.
[13] S. Majumdar,et al. Impact of mucoadhesive agent inclusion on the intraocular pressure lowering profile of Δ9-tetrahydrocannabinol-valine-hemisuccinate loaded nanoemulsions in New Zealand white rabbits. , 2022, International journal of pharmaceutics.
[14] K. Swindle-Reilly,et al. Considerations for Polymers Used in Ocular Drug Delivery , 2022, Frontiers in Medicine.
[15] J. Álvarez-Fuentes,et al. Receptor-targeted nanoparticles modulate cannabinoid anticancer activity through delayed cell internalization , 2022, Scientific reports.
[16] H. Turner,et al. Potential Use for Chronic Pain: Poly(Ethylene Glycol)-Poly(Lactic-Co-Glycolic Acid) Nanoparticles Enhance the Effects of Cannabis-Based Terpenes on Calcium Influx in TRPV1-Expressing Cells. , 2022, International journal of pharmaceutics.
[17] E. Messmer. Pathophysiology of dry eye disease and novel therapeutic targets. , 2022, Experimental eye research.
[18] M. Cordeiro,et al. VSN16S, an agonist of the cannabinoid receptor, reduces IOP profiles and exhibits neuroprotective properties in a rat model of glaucoma , 2022, Acta ophthalmologica.
[19] A. Camins,et al. Lipid Nanoparticles for the Posterior Eye Segment , 2021, Pharmaceutics.
[20] U. Gehlsen,et al. Topical application of cannabinoid-ligands ameliorates experimental dry-eye disease. , 2021, The ocular surface.
[21] A. Rodrigues,et al. Pickering emulsions stabilized with chitosan/collagen peptides nanoparticles as green topical delivery vehicles for cannabidiol (CBD) , 2021, Colloids and Surfaces A: Physicochemical and Engineering Aspects.
[22] Qipeng Yuan,et al. Enhanced bioavailability and biosafety of cannabidiol nanomicelles for effective anti-inflammatory therapy , 2021, Particuology.
[23] A. Sosnik,et al. Cannabidiol-Loaded Mixed Polymeric Micelles of Chitosan/Poly(Vinyl Alcohol) and Poly(Methyl Methacrylate) for Trans-Corneal Delivery , 2021, Pharmaceutics.
[24] B. Rebesco,et al. Innovative Clinical-Organizational Model to Ensure Appropriateness and Quality in the Management of Medical Cannabis: An Italian Regional Case , 2021, Healthcare.
[25] G. Ousler,et al. Repository Corticotropin Injection (Acthar® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study , 2021, Ophthalmology and Therapy.
[26] A. Hauser,et al. Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development , 2021, Frontiers in Medicine.
[27] J. Crecente‐Campo,et al. Nanotechnologies for the delivery of biologicals: historical perspective and current landscape. , 2021, Advanced drug delivery reviews.
[28] R. Löbenberg,et al. Development of a novel cannabinoid-loaded microemulsion towards an improved stability and transdermal delivery. , 2021, International journal of pharmaceutics.
[29] T. Wong,et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. , 2021, Ophthalmology.
[30] Laureano Schofs,et al. The antimicrobial effect behind Cannabis sativa , 2021, Pharmacology research & perspectives.
[31] H. Dua,et al. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance , 2021, Eye.
[32] A. L. Ruela,et al. Mucoadhesive nanostructured lipid carriers as a cannabidiol nasal delivery system for the treatment of neuropathic pain. , 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[33] Ji-Peng Olivia Li,et al. CannabinEYEds: The Endocannabinoid System as a Regulator of the Ocular Surface Nociception, Inflammatory Response, Neovascularization and Wound Healing , 2020, Journal of clinical medicine.
[34] R. Dana,et al. Defining Dry Eye from a Clinical Perspective , 2020, International journal of molecular sciences.
[35] S. Majumdar,et al. Effect of surfactant concentration and sterilization process on intraocular pressure–lowering activity of Δ9-tetrahydrocannabinol-valine-hemisuccinate (NB1111) nanoemulsions , 2020, Drug Delivery and Translational Research.
[36] S. MacNeil,et al. Corneal Infection Models: Tools to Investigate the Role of Biofilms in Bacterial Keratitis , 2020, Cells.
[37] S. Kang,et al. Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery. , 2020, Journal of controlled release : official journal of the Controlled Release Society.
[38] Li Yang,et al. Solid lipid nanoparticles loading with curcumin and dexanabinol to treat major depressive disorder , 2020, Neural Regeneration Research.
[39] R. Ross,et al. Evidence that cannabinoid CB1 receptors regulate intraocular pressure via two opposing mechanisms. , 2020, Experimental eye research.
[40] H. Rupasinghe,et al. Industrial Hemp (Cannabis sativa subsp. sativa) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals , 2020, Molecules.
[41] L. Rodríguez-Rodríguez,et al. Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review. , 2020, Seminars in arthritis and rheumatism.
[42] H. Danesh-Meyer,et al. Cannabinoids and the eye. , 2020, Survey of ophthalmology.
[43] H. Makarenkova,et al. THC Regulates Tearing via Cannabinoid CB1 Receptors , 2020, Investigative ophthalmology & visual science.
[44] Michael Ansong,et al. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration , 2020, Expert opinion on drug metabolism & toxicology.
[45] I. Greenwood,et al. Cyclic AMP-Dependent Regulation of Kv7 Voltage-Gated Potassium Channels , 2020, Frontiers in Physiology.
[46] N. Garg,et al. The Impact of Marijuana on the Cardiovascular System: A Review of the Most Common Cardiovascular Events Associated with Marijuana Use , 2020, Journal of clinical medicine.
[47] F. Otero-Espinar,et al. Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations , 2020, Pharmaceutics.
[48] W. Hall,et al. Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study. , 2020, The International journal on drug policy.
[49] R. Dana,et al. Advances and limitations of drug delivery systems formulated as eye drops. , 2020, Journal of controlled release : official journal of the Controlled Release Society.
[50] G. Thakur,et al. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation , 2020, Molecules.
[51] S. Schwartz,et al. Diabetic Retinopathy–An Underdiagnosed and Undertreated Inflammatory, Neuro-Vascular Complication of Diabetes , 2019, Front. Endocrinol..
[52] P. Lebranchu,et al. Efficacy and Safety of Interferon Alpha 2A and Pegylated Interferon Alpha 2A in Inflammatory Macular Edema , 2019, Ocular immunology and inflammation.
[53] M. Guida,et al. Prevention of Pseudomonas aeruginosa Biofilm Formation on Soft Contact Lenses by Allium sativum Fermented Extract (BGE) and Cannabinol Oil Extract (CBD) , 2019, Antibiotics.
[54] G. Yiu,et al. Emerging Concepts in the Treatment of Diabetic Retinopathy , 2019, Current Diabetes Reports.
[55] Rakan S. Al-Essa,et al. Primary congenital glaucoma: An updated review , 2019, Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society.
[56] E. Sánchez-López,et al. Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents , 2019, Pharmaceutics.
[57] W. Guba,et al. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis , 2019, Molecules.
[58] S. Majumdar,et al. Δ9-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits , 2019, Translational vision science & technology.
[59] M. Breunig,et al. Causative glaucoma treatment: promising targets and delivery systems. , 2019, Drug discovery today.
[60] M. Alonso,et al. Oral Delivery of Biologics for Precision Medicine , 2019, Advanced materials.
[61] S. Majumdar,et al. Analog Derivatization of Cannabidiol for Improved Ocular Permeation. , 2019, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[62] M. Elsohly,et al. New trends in cannabis potency in USA and Europe during the last decade (2008–2017) , 2019, European Archives of Psychiatry and Clinical Neuroscience.
[63] H. Bradshaw,et al. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure , 2018, Investigative ophthalmology & visual science.
[64] E. Groce. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research , 2018, Journal of Medical Regulation.
[65] K. Greish,et al. Synthetic cannabinoids nano‐micelles for the management of triple negative breast cancer , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[66] H. Bradshaw,et al. Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye. , 2018, Prostaglandins & other lipid mediators.
[67] V. Mishra,et al. Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems , 2018, Pharmaceutics.
[68] Shan C. Lin,et al. Epidemiology of uveitis in a US population-based study , 2018, Journal of Ophthalmic Inflammation and Infection.
[69] D. Pachito,et al. Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews , 2018, Phytotherapy research : PTR.
[70] Vikramaditya G. Yadav,et al. A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery , 2018, Drug Delivery and Translational Research.
[71] D. Thapa,et al. The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation , 2018, Cannabis and cannabinoid research.
[72] N. M. di Luca,et al. Medical use of cannabis: Italian and European legislation. , 2018, European review for medical and pharmacological sciences.
[73] J. Micó,et al. Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days. , 2017, Nanomedicine : nanotechnology, biology, and medicine.
[74] S. Majumdar,et al. Ocular Disposition of ∆8-Tetrahydrocannabinol from Various Topical Ophthalmic Formulations , 2017, AAPS PharmSciTech.
[75] F. Atyabi,et al. Application of carbon nanotubes as the carriers of the cannabinoid, 2‐arachidonoylglycerol: Towards a novel treatment strategy in colitis , 2017, Life sciences.
[76] M. Alonso,et al. Synthetic nanocarriers for the delivery of polynucleotides to the eye , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[77] Farooq Ali Khan,et al. Nanoemulsion: Concepts, development and applications in drug delivery , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[78] Amira M. El-Ganiny,et al. Prevention of Bacterial Biofilm Formation on Soft Contact Lenses Using Natural Compounds , 2017, Journal of Ophthalmic Inflammation and Infection.
[79] S. Majumdar,et al. Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability , 2017, Investigative ophthalmology & visual science.
[80] A. Mitra,et al. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[81] B. Johnston,et al. Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy , 2017, Neuropharmacology.
[82] Sai Prachetan Balguri,et al. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[83] F. Muñoz-Negrete,et al. Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease. , 2016, Investigative ophthalmology & visual science.
[84] Mei Wang,et al. Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression , 2016, International journal of nanomedicine.
[85] J. Toguri,et al. Turning Down the Thermostat: Modulating the Endocannabinoid System in Ocular Inflammation and Pain , 2016, Front. Pharmacol..
[86] S. Panchal,et al. Effect of potassium channel openers in acute and chronic models of glaucoma , 2016, Taiwan Journal of Ophthalmology.
[87] Lina Yu,et al. Mesoporous Silica Particles as a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy , 2016, Advanced healthcare materials.
[88] T. Tolker-Nielsen,et al. Pseudomonas aeruginosa Biofilm Infections: Community Structure, Antimicrobial Tolerance and Immune Response. , 2015, Journal of molecular biology.
[89] R. Beuerman,et al. Corneal Biofilms: From Planktonic to Microcolony Formation in an Experimental Keratitis Infection with Pseudomonas Aeruginosa. , 2015, The ocular surface.
[90] M. de la Fuente,et al. Nanotherapies for the treatment of ocular diseases. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[91] Eneida Pérez Candelaria,et al. Corneal ulcers in contact lens wearers , 2015 .
[92] K. Greish,et al. Effect of styrene maleic acid WIN55,212-2 micelles on neuropathic pain in a rat model , 2015, Journal of drug targeting.
[93] M. Gilmore,et al. Biofilms in Infections of the Eye , 2015, Pathogens.
[94] Lídia M D Gonçalves,et al. Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids , 2015, Journal of Nanoparticle Research.
[95] Leopold Schmetterer,et al. Pharmacotherapy of glaucoma. , 2015, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[96] L. Martin-Banderas,et al. Engineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms. , 2014, Colloids and surfaces. B, Biointerfaces.
[97] R. Laprairie,et al. Anti‐inflammatory effects of cannabinoid CB2 receptor activation in endotoxin‐induced uveitis , 2014, British journal of pharmacology.
[98] Ruchira Singh,et al. CB1 cannabinoid receptor agonist prevents NGF-induced sensitization of TRPV1 in sensory neurons , 2013, Neuroscience Letters.
[99] S. Sharma,et al. Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat. , 2013, Experimental eye research.
[100] L. Marnett,et al. Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 1-induced inflammatory responses to corneal injury. , 2013, Cellular signalling.
[101] M. A. Holgado,et al. Development and Validation of an RP-HPLC Method for CB13 Evaluation in Several PLGA Nanoparticle Systems , 2012, TheScientificWorldJournal.
[102] B. Klein,et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.
[103] H. Quigley. Glaucoma , 2011, The Lancet.
[104] Yolanda Diebold,et al. Applications of nanoparticles in ophthalmology , 2010, Progress in Retinal and Eye Research.
[105] Justine R. Smith,et al. Education in the ophthalmic discipline of uveitis. , 2008, American journal of ophthalmology.
[106] J. Forrester,et al. Anti‐inflammatory property of the cannabinoid receptor‐2‐selective agonist JWH‐133 in a rodent model of autoimmune uveoretinitis , 2007, Journal of leukocyte biology.
[107] Y. Khalifa,et al. Neuroprotective and Intraocular Pressure-Lowering Effects of (–)Δ9-Tetrahydrocannabinol in a Rat Model of Glaucoma , 2007, Ophthalmic Research.
[108] M. Zierhut,et al. Adalimumab in the therapy of uveitis in childhood , 2006, British Journal of Ophthalmology.
[109] R. Pertwee,et al. Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study , 2006, Journal of glaucoma.
[110] P. Shek,et al. Ocular hypotensive effects of an intratracheally delivered liposomal delta9-tetrahydrocannabinol preparation in rats. , 2006, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[111] A. Zuardi. History of cannabis as a medicine: a review. , 2006, Revista brasileira de psiquiatria.
[112] D. Cota,et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.
[113] Y. Khalifa,et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. , 2005, The American journal of pathology.
[114] S. Kingman. Glaucoma is second leading cause of blindness globally. , 2004, Bulletin of the World Health Organization.
[115] B. Godin,et al. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[116] R. Caldwell,et al. Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. , 2003, The American journal of pathology.
[117] P. Foster,et al. The definition and classification of glaucoma in prevalence surveys , 2002, The British journal of ophthalmology.
[118] G. Gessa,et al. The synthetic cannabinoid WIN55212‐2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies , 2001, The European journal of neuroscience.
[119] Loftssona,et al. Cyclodextrins in ophthalmic drug delivery. , 1999, Advanced drug delivery reviews.
[120] J. H. Liu,et al. Central nervous system and peripheral mechanisms in ocular hypotensive effect of cannabinoids. , 1987, Archives of ophthalmology.
[121] R. W. Wood,et al. Ocular disposition of poly-hexyl-2-cyano[3-14C]acrylate nanoparticles in the albino rabbit , 1985 .
[122] K. Green,et al. Multiple-Drop Study of Topically Applied 1% Δ9-Tetrahydrocannabinol in Human Eyes , 1983 .
[123] J. Tiedeman,et al. Effect of synthetic cannabinoids on elevated intraocular pressure. , 1981, Ophthalmology.
[124] W. J. Crawford,et al. Effect of marihuana on intraocular and blood pressure in glaucoma. , 1980, Ophthalmology.
[125] M. Luntz. Congenital, infantile, and juvenile glaucoma. , 1979, Ophthalmology.
[126] K. Green,et al. A comparison of topical cannabinoids on intraocular pressure. , 1978, Experimental eye research.
[127] J. Gregg,et al. Effect of Delta‐9-Tetrahydrocannabinol on Intraocular Pressure in Humans , 1977, Southern medical journal.
[128] S. Cohen,et al. THE 94‐DAY CANNABIS STUDY , 1976, Annals of the New York Academy of Sciences.
[129] R. Hepler,et al. Marihuana smoking and intraocular pressure. , 1971, JAMA.
[130] C. Baudouin,et al. [Primary open-angle glaucoma]. , 2018, La Revue de medecine interne.
[131] M. Jamal,et al. Bacterial biofilm and associated infections. , 2018, Journal of the Chinese Medical Association : JCMA.
[132] S. Doktorovová,et al. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye – Part I – Barriers and determining factors in ocular delivery , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[133] P. Lehoang. The gold standard of noninfectious uveitis: corticosteroids. , 2012, Developments in ophthalmology.
[134] S. Pinar-Sueiro,et al. Aplicaciones de los cannabinoides en glaucoma , 2011 .
[135] E. Vecino,et al. Cannabinoid applications in glaucoma , 2011 .
[136] L. M. Calvo Hernández,et al. [Uveitis: a challenge for internist]. , 2008, Anales de Medicina Interna.
[137] J. Winston,et al. Causes of Uveitis in the General Practice of Ophthalmology , 1996 .
[138] S. Almog,et al. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. , 1992, Ophthalmic research.
[139] M. Elsohly,et al. Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit. , 1984, Current eye research.
[140] K. Green,et al. Intraocular pressure following systemic administration of cannabinoids. , 1982, Current eye research.
[141] R. Mechoulam,et al. Marijuana ; chemistry, pharmacology, metabolism and clinical effects , 1973 .